Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 7;29(37):5305-5312.
doi: 10.3748/wjg.v29.i37.5305.

Sequence of events leading to primary biliary cholangitis

Affiliations
Review

Sequence of events leading to primary biliary cholangitis

Ilaria Lenci et al. World J Gastroenterol. .

Abstract

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that is observed more frequently in middle-aged women. This disorder is considered an autoimmune disease, since liver injury is sustained by the presence of self-directed antimitochondrial antibodies targeting the bile duct cells. The prognosis may vary depending on an early diagnosis and response to therapy. However, nearly a third of patients can progress to liver cirrhosis, thus requiring a liver transplant. Traditional immunosuppressive therapies, commonly employed for other autoimmune diseases, have limited effects on PBC. In fact, dramatic functional changes that occur in the biliary epithelium in the course of inflammation play a major role in perpetuating the injury. In this minireview, after a background on the disease and possible predisposing factors, the sequential cooperation of cellular/molecular events leading to end-stage PBC is discussed in detail. The rise and maintenance of the autoimmune process, as well as the response of the biliary epithelia during inflammatory injury, are key factors in the progression of the disease. The so-called "ductular reaction (DR)", intended as a reactive expansion of cells with biliary phenotype, is a process frequently observed in PBC and partially understood. However, recent findings suggest a strict relationship between this pathological picture and the progression to liver fibrosis, cell senescence, and loss of biliary ducts. All these issues (onset of chronic inflammation, changes in secretive and proliferative biliary functions, DR, and its relationship with other pathological events) are discussed in this manuscript in an attempt to provide a snapshot, for clinicians and researchers, of the most relevant and sequential contributors to the progression of this human cholestatic disease. We believe that interpreting this disorder as a multistep process may help identify possible therapeutic targets to prevent evolution to severe disease.

Keywords: Antimitochondrial antibody; Biliary proliferation; Biliary secretion; Cellular senescence; Cholangiocyte; Ductular reaction; Liver fibrosis; Primary biliary cholangitis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Figures

Figure 1
Figure 1
From immune mediated damage to bile acids injury. In primary biliary cholangitis the inflammatory process induces a decrease in chloride-bicarbonate exchangerexpression. This in turn determines a reduction of bicarbonate film (bicarbonate umbrella) on the canalicular portion of bile duct cells, exposing them to hydrophobic bile acids injury. AE2: Chloride-bicarbonate exchanger.
Figure 2
Figure 2
Central role of ductular reaction in the progression of primary biliary cholangitis. Ductular reaction contributes to the activation of hepatic stellate cells and simultaneously favours a cell senescent phenotype. These events support the ductopenic/cirrhotic evolution of liver tissue during this cholestatic disease. PBC: Primary biliary cholangitis; SASP: Senescence-associated secretory phenotype.

Similar articles

Cited by

References

    1. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. Am J Gastroenterol. 2015;110:1536–1538. - PMC - PubMed
    1. Heathcote EJ. Primary biliary cirrhosis: historical perspective. Clin Liver Dis. 2003;7:735–740. - PubMed
    1. Sherlock S. Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice) Gastroenterology. 1959;37:574–586. - PubMed
    1. Colapietro F, Lleo A, Generali E. Antimitochondrial Antibodies: from Bench to Bedside. Clin Rev Allergy Immunol. 2022;63:166–177. - PMC - PubMed
    1. Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM. Diagnosis and Management of Primary Biliary Cholangitis. Am J Gastroenterol. 2019;114:48–63. - PubMed